Now truly is an exciting time for molecular radionuclide therapy and theranostics in general. Having worked in the field of radiobiology since 2006 and radionuclide imaging of cancer and rheumatoid arthritis since 2014, I now focus on taking a step back and trying to truly understand how best to use radionuclides for effective molecular radionuclide therapy with mimimal healthy tissue toxicity. In this presentation, I will highlight this need to truly understand how the absorbed dose (the 'Gy') relates to biological effects for a range of radionuclides, not just for patients but also technologists, and showcase how the field might best move forward.
Dr Terry is a Senior Lecturer in Radiobiology at King's College London and has built a research programme in Radiobiology of molecular radiotherapy in cancer with an overall aim to enhance understanding of the effect of therapeutic radionuclides on cancer and healthy tissues, create more effective precision radionuclide therapeutics, tailor them to patients and predict side effects. With over 15 years radiobiological expertise, she has previously worked as a postdoctoral researcher at King's College London (radionuclide imaging of multiple myeloma), Roche postdoctoral fellow at the Radboud UMC, the Netherlands (radionuclide imaging of tumour microenvironment and arthritis), Postdoctoral researcher at University of Oxford (targeted radionuclide therapy and the effect of chromatin density), and PhD student at the University of St Andrews (how chromosomes are damaged after external beam irradiation).